Previous close | 20.60 |
Open | 20.66 |
Bid | 21.98 x 100 |
Ask | 22.17 x 100 |
Day's range | 20.37 - 22.51 |
52-week range | 3.60 - 28.15 |
Volume | |
Avg. volume | 513,098 |
Market cap | 857.112M |
Beta (5Y monthly) | 1.25 |
PE ratio (TTM) | N/A |
EPS (TTM) | -2.25 |
Earnings date | 01 Aug 2024 - 05 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 41.22 |
We can readily understand why investors are attracted to unprofitable companies. Indeed, Longboard Pharmaceuticals...
LA JOLLA, Calif., May 06, 2024--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the grant of inducement awards to seven new employees. The Compensation Committee of the Board of Directors of Longboard approved the grants of non-qualified stock options to purchase an aggregate of 178,000 shares of its common stock (the "Common Stock") as inducements material
Insight into Longboard Pharmaceuticals' First Quarter Performance and Future Outlook